NCT02506959 2025-03-18
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
7 trialsNCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
NCT01237951 2020-05-05
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00003401 2019-10-17
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
University of Maryland, Baltimore
Phase 2 Completed
NCT02791373 2018-04-03
ViGeM
Insel Gruppe AG, University Hospital Bern
Phase 2 Completed
NCT00477035 2017-01-11
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
Stanford University
Phase 1 Completed
NCT00410982 2016-06-03
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed